1005484-25-2

Basic information

• Product Name: 1-(4-nitrobenzyl)-2-(1,4,7-triazacyclononan-1-yl)ethylamine
• Synonyms: 1-(4-nitrobenzyl)-2-(1,4,7-triazacyclononan-1-yl)ethylamine
• CAS NO: 1005484-25-2
• Molecular Weight: 307.396
• Mol File: 1005484-25-2.mol

Chemical Properties

• CAS DataBase Reference: 1-(4-nitrobenzyl)-2-(1,4,7-triazacyclononan-1-yl)ethylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-nitrobenzyl)-2-(1,4,7-triazacyclononan-1-yl)ethylamine(1005484-25-2)
• EPA Substance Registry System: 1-(4-nitrobenzyl)-2-(1,4,7-triazacyclononan-1-yl)ethylamine(1005484-25-2)

Safety Data

• Hazardous Substances Data: 1005484-25-2(Hazardous Substances Data)

Upstream product

• 1005484-24-1 1,4-di-tert-butyl 7-(2-{[(tert-butoxy)carbonyl]amino}-3-(4-nitrophenyl)propyl)-1,4,7-triazonane-1,4-dicarboxylate 
• 1353022-73-7 2-[(4-methylphenyl)sulfonamido]-3-(4-nitrophenyl)propanamide 
• 1353022-74-8 N-[1-amino-3-(4-nitrophenyl)propan-2-yl]-4-methylbenzene-1-sulfonamide 
• 1258945-86-6 tert-butyl N-[1-(4-nitrophenyl)-3-oxopropan-2-yl]carbamate 
• 174138-01-3 1,4-di-tert-butyl 1,4,7-triazonane-1,4-dicarboxylate 
• 1353022-72-6 N-(1-{4,7-bis[(4-methylphenyl)sulfonyl]-1,4,7-triazonan-1-yl}-3-(4-nitrophenyl)propan-2-yl)-4-methylbenzene-1-sulfonamide 
• 105359-56-6 2-amino-3-(4-nitrophenyl)propanamide 
• 85317-52-8 methyl 2-amino-3-(4-nitrophenyl)propionate 
• 89288-22-2 2-amino-3-(4-nitrophenyl)propan-1-ol 
• 95388-08-2 N,N'-bis(p-toluenesulfonyl)-1,4,7-triazacyclononane 

Downstream Products

• 1041634-52-9 {4-carboxymethyl-7-[2-(carboxymethyl-amino)-3-(4-isothiocyanato-phenyl)-propyl]-[1,4,7]-triazonan-1-yl}-acetic acid 
• 1173056-35-3 2-[(1-{4-[(4R)-4-[(1S,2S,5R,7S,9R,10R,11S,14R,15R,16S)-5-amino-9,16-dihydroxy-2,15-dimethyltetracyclo[8.7.0.02,7.011,15]heptadecan-14-yl]pentanamido]phenyl}-3-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]propan-2-yl)amino]acetic acid 
• 1173056-38-6 2-({1-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]-3-{4-[(4R)-4-[(1S,2S,5R,7S,9R,10R,11S,14R,15R,16S)-9,16-dihydroxy-2,15-dimethyl-5-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]tetracyclo[8.7.0.02,7.011,15]heptadecan-14-yl]pentanamido]phenyl}propan-2-yl}amino)acetic acid 
• 1173056-20-6 [4-carboxymethyl-7-(2-(carboxymethyl-amino)-3-{4-[(R)-4-((3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-cyclopenta[a]phenanthren-17-yl)-pentanoylamino]phenyl}-propyl)-[1,4,7]triazonan-1-yl]-acetic acid 
• 1173056-18-2 [4-carboxymethyl-7-(2-(carboxymethyl-amino)-3-{4-[(R)-4-((3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-cyclopenta[a]phenanthren-17-yl)-pentanoylamino]-phenyl}-propyl)-[1,4,7]triazonan-1-yl]-acetic acid 
• 1173056-12-6 [4-tert-butoxycarbonylmethyl-7-(2-(tert-butoxycarbonyl methyl-amino)-3-{4-[(R)-4-((3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-pentanoylamino]-phenyl}-propyl)-[1,4,7]triazonan-1-yl]-acetic acid tert-butyl ester 
• 1173056-11-5 [4-tert-butoxycarbonylmethyl-7-(2-(tert-butoxycarbonylmethyl-amino)-3-{4-[(R)-4-((3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-pentanoylamino]-phenyl}-propyl)-[1,4,7]triazonan-1-yl]-acetic acid tert-butyl ester 
• 1041634-50-7 {4-[3-(4-amino-phenyl)-2-(carboxymethyl-amino)-propyl]-7-carboxymethyl-[1,4,7]triazonan-1-yl}-acetic acid 
• 1016237-83-4 tert-butyl {4-[3-(4-amino-phenyl)-2-(tert-butoxycarbonylmethyl-amino)-propyl]-7-tert-butoxycarbonylmethyl-[1,4,7]triazonan-1-yl}-acetate 
• 1016237-90-3 {4-carboxymethyl-7-[2-(carboxymethyl-amino)-3-(4-nitro-phenyl)-propyl]-[1,4,7]-triazonan-1-yl}-acetic acid 
• 1029127-63-6 t-butyl [4-tert-butoxycarbonylmethyl-7-(2-(tert-butoxycarbonylmethyl-amino)-3-{4-[(R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-pentanoylamino]-phenyl}-propyl)-[1,4,7]-triazonan-1-yl]acetate 
• 1016237-87-8 (4-carboxymethyl-7-{2-(carboxymethyl-amino)-3-[4-(7-nitro-benzo[1,2,5]oxadiazol-4-ylamino)-phenyl]-propyl}-[1,4,7]triazonan-1-yl)-acetic acid 
• 1016237-85-6 t-butyl (4-tert-butoxycarbonylmethyl-7-{2-(tert-butoxycarbonylmethyl-amino)-3-[4-(7-nitro-benzo[1,2,5]oxadiazol-4-ylamino)-phenyl]-propyl}-[1,4,7]triazonan-1-yl)-acetate 
• 1173056-33-1 1-[(2S,5R,9R,15R,16S)-14-{4-[(4-{3-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]-2-[bis(carboxymethyl)amino]propyl}phenyl)carbamoyl]butan-2-yl}-9,16-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0(2,7).0(11,15)]heptadecan-5-yl]triaz-2-yn-2-ium-1-ide 

Relevant articles and documents

Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using

Substituted 1,4,7-triazacyclononane-N,N′,N″-triacetic acid and 1,4,7,10-tetraazacyclcododecane-N,N′,N″,N′″-tetraacetic acid compounds with a pendant amino or hydroxyl group, metal complexes thereof, compositions thereof, and methods of making and use in diagnostic imaging and treatment of cellular disorders.

Synthesis and evaluation of an enantiomerically enriched bifunctional chelator for 64Cu-based positron emission tomography (PET) imaging

We report the synthesis and evaluation of an enantiomerically enriched bifunctional chelator, (S)-C-NE3TA. The bifunctional chelator was efficiently prepared by regioselective and stereoselective ring opening of an aziridinium ion. The new chiral chelator instantly and almost completely bound to 64Cu at room temperature. The corresponding 64Cu- radiolabeled complex remained intact in human serum for 48 h without any measurable transchelation and was tolerant to a rigorous EDTA challenge for 24 h. The 64Cu-radiolabeled (S)-C-NE3TA complex was stable in mice and produced an excellent biodistribution profile. The results of the in vitro and in vivo evaluations indicate that the new optically active chelator is a promising candidate for PET imaging applications. We report an enantiomerically enriched bifunctional ligand in the NE3TA series for the first time. The chelator instantly bound to 64Cu to form a complex that was stable in vitro and in vivo and possesses great promise for use in targeted positron emission topography (PET) imaging. Copyright

Synthesis and Evaluation of an Enantiomerically Enriched Bifunctional Chelator for 64Cu-Based Positron Emission Tomography (PET) Imaging

We report the synthesis and evaluation of an enantiomerically enriched bifunctional chelator, (S)-C-NE3TA. The bifunctional chelator was efficiently prepared by regioselective and stereoselective ring opening of an aziridinium ion. The new chiral chelator instantly and almost completely bound to 64Cu at room temperature. The corresponding 64Cu-radiolabeled complex remained intact in human serum for 48 h without any measurable transchelation and was tolerant to a rigorous EDTA challenge for 24 h. The 64Cu-radiolabeled (S)-C-NE3TA complex was stable in mice and produced an excellent biodistribution profile. The results of the in vitro and in vivo evaluations indicate that the new optically active chelator is a promising candidate for PET imaging applications.

Convenient synthesis and evaluation of a heptadentate bifunctional ligand for radioimmunotherapy applications

An efficient synthetic route to a bifunctional chelating agent C-NE3TA-NCS for antibody-targeted radioimmunotherapy (RIT) applications was developed. Various synthetic methods centered on key reaction steps, including bimolecular cyclization, ring-opening